AI Article Synopsis
- Glioblastoma is a highly aggressive brain tumor with limited treatment options, and studying its molecular subtypes could improve prognosis and therapy development.
- A research study analyzed tumor samples from 432 patients to compare the TCGA and IGS classification systems for glioblastoma using tissue microarrays and RNA sequencing.
- The results showed inconsistent classifications between the two systems, revealing that individual gene expressions are better predictors of patient survival than the broad molecular subtypes themselves, suggesting a need for refinement in these classification methods before clinical application.
Article Abstract
Purpose: Glioblastoma is the most aggressive brain tumor in adults and has few therapeutic options. The study of molecular subtype classifications may lead to improved prognostic classification and identification of new therapeutic targets. The Cancer Genome Atlas (TCGA) subtype classification has mainly been applied in U.S. clinical trials, while the intrinsic glioma subtype (IGS) has mainly been applied in European trials.
Experimental Design: From paraffin-embedded tumor samples of 432 patients with uniformly treated, newly diagnosed glioblastoma, we built tissue microarrays for IHC analysis and applied RNA sequencing to the best samples to classify them according to TCGA and IGS subtypes.
Results: We obtained transcriptomic results from 124 patients. There was a lack of agreement among the three TCGA classificatory algorithms employed, which was not solely attributable to intratumoral heterogeneity. There was overlapping of TCGA mesenchymal subtype with IGS cluster 23 and of TCGA classical subtype with IGS cluster 18. Molecular subtypes were not associated with prognosis, but levels of expression of 13 novel genes were identified as independent prognostic markers in glioma-CpG island methylator phenotype-negative patients, independently of clinical factors and methylation. These findings were validated in at least one external database. Three of the 13 genes were selected for IHC validation. In particular, high RNA expression and low ZNF7 protein expression were strongly associated with longer survival, independently of molecular subtypes.
Conclusions: TCGA and IGS molecular classifications of glioblastoma have no higher prognostic value than individual genes and should be refined before being applied to clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-20-2141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Qualitative Method to Detect Paraproteins from Serum Using Ultra Performance Liquid Chromatography Electrospray Triple Quadrupole Mass Spectrometry.
J Appl Lab Med
March 2024
R&D, Neuberg Anand Academy of Laboratory Medicine Pvt. Ltd., Bengaluru, India.
Background: Mass spectrometry-based techniques are increasingly reported in the literature for identifying paraproteins due to their improved specificity and sensitivity. The present study demonstrates the capability of ultra performance liquid chromatography (UPLC) electrospray ionization triple quadrupole mass spectrometry for the qualitative analysis of paraproteins.
Methods: Paraproteins from patient serum (n = 40) were immunopurified using agarose beads coated with camelid antibodies that are specific for various subtypes of immunoglobulins (Igs; G, A, M, and light chains κ, λ).
Breast milk immune composition varies during the transition stage of lactation: characterization of immunotypes in the MAMI cohort.
Front Nutr
November 2023
Physiology Section, Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona (UB), Barcelona, Spain.
Article Synopsis
- Breast milk contains vital immune components, including various immunoglobulins (Igs), cytokines, and adipokines, which are essential for infant health, particularly during the transitional lactation stage.
- Significant differences in the levels of Igs and cytokines were observed between days 7 and 15 postpartum, indicating that breast milk composition changes rapidly during this time.
- The study identified two distinct maternal immune profiles based on the evolution of breast milk immune factors, suggesting that individual variations in milk composition may be influenced by factors like maternal characteristics and breastfeeding practices.
An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
Vaccine
August 2023
Vaxine Pty Ltd, Bedford Park, Adelaide, SA 5042, Australia. Electronic address:
There is a major unmet need for strategies to improve the immunogenicity and effectiveness of pandemic influenza vaccines, particularly in poor responder populations such as neonates. Recombinant protein approaches to pandemic influenza offer advantages over more traditional inactivated virus approaches, as they are free of problems such as egg adaptation or need for high level biosecurity containment for manufacture. However, a weakness of recombinant proteins is their low immunogenicity.
View Article and Find Full Text PDFDiagnosis and prognosis prediction model for digestive system tumors based on immunologic gene sets.
Front Oncol
March 2023
School of Biological and Environmental Engineering, Chaohu University, Chaohu, Anhui, China.
According to 2020 global cancer statistics, digestive system tumors (DST) are ranked first in both incidence and mortality. This study systematically investigated the immunologic gene set (IGS) to discover effective diagnostic and prognostic biomarkers. Gene set variation (GSVA) analysis was used to calculate enrichment scores for 4,872 IGSs in patients with digestive system tumors.
View Article and Find Full Text PDFSpecific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.
Neurol Neuroimmunol Neuroinflamm
January 2023
From the Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany and Brain and Mind Center, University of Sydney, Australia; The Blizard Institute (K.S.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience) (K.S.), The Royal London Hospital, Barts Health NHS Trust, UK; Ingham Institute for Applied Medical Research (S.H.), University of New South Wales Medicine, Sydney, Australia; Department of Neurology (T.D.), University Hospital Basel, Switzerland; Department of Neurology (Andrew Chan), Inselspital, Bern University Hospital, University of Bern, Switzerland; Danish MS Center (F.S.), Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine (F.S.), University of Copenhagen, Denmark; Multiple Sclerosis Center (A.A.), Sheba Academic Medical Center, Ramat Gan, Israel; Sackler School of Medicine (A.A.), Tel-Aviv University, Israel; Department of Neurology-Neuroimmunology (X.M.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain; Department of Neurosciences and CRCHUM (A.P.), Université de Montréal, QC, Canada; Department of Neurological and Behavioural Sciences (N.D.S.), University of Siena, Italy; Department of Radiology (F.B.), VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology (F.B.), London, UK; Experimental Neurophysiology Unit (L.L.), Vita-Salute San Raffaele University, Milan, Italy; Univ. Lille (P.V.), Inserm U1172 LilNCog, CHU Lille, FHU Precise, France; Cytel Inc (Anita Chudecka), Geneva, Switzerland; InScience Communications (C.M.), Springer Healthcare Ltd, Chester, UK; EMD Serono (K.H.H.), Billerica, MA; and Ares Trading SA (U.B., S.R.), Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
Article Synopsis
- Cladribine tablets lead to significant decreases in B-cell and T-cell counts in patients with highly active relapsing multiple sclerosis, with the most pronounced effects on B-cell subtypes.* -
- A study involving 57 patients tracked changes in immune cell counts over 12 months, showing that B-cell counts hit their lowest points by month 2 while T-cell changes were slower and less intense.* -
- The findings indicate a unique immune response to cladribine, with notable B-cell depletion and slower recovery of certain T-cell populations, providing insights into the drug's effects on the immune system.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!